HeartSciences' MyoVista Technology Used to Develop AI-ECG Algorithm to Identify Patients

"Skip to content\nHome\nProducts\nClinical\nNews\nInvestors\nAbout Us\nContact Us\nINVEST NOW\nNEWS\nHeartSciences’ MyoVista Technology Used to Develop AI-ECG Algorithm to Identify Patients\nNovember 14, 2022\n\na day ago–#artificialintelligence \n\nHeart Test Laboratories, d/b/a HeartSciences, a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of AI, announced that an independent study utilizing its MyoVista proprietary technology was featured in Advocate Aurora Health’s Journal of Patient-Centered Research and Reviews, an open access, peer-reviewed medical journal devoted to advancing patient centered care practices, health outcomes, and patient experiences. The publication concluded that the MyoVista technology ECG-derived machine learning model “provides a cost-effective strategy for predicting patient subgroups in whom an integrated milieu of systolic and diastolic dysfunction is associated with a high-risk of major adverse cardiovascular events (MACE).” “This independent study demonstrates the opportunity that AI-ECG algorithms could bring to improving health outcomes. I believe the solution to unnecessary cardiac deaths will come from low-cost, front-line screening using AI-ECGs. Imagine the day where you can go to your primary care physician and a simple 20-second ECG test shows not only whether you have early-stage heart disease, but also whether you are at high-risk of a major adverse cardiovascular event in the next three years,” stated Andrew Simpson, CEO of HeartSciences.\n\nContacts\nMEDIA RELATIONS\n\nGene Gephart\nDirector of Marketing\n+1-682-244-2578 (US)\n\ngene.gephart@heartsciences.com\nINVESTOR CONTACT\n\nMark Komonoski – Partner\nIntegrous Communications\nDirect: 877-255-8483\n\ninvestorrelations@heartsciences.com\nwww.integcom.us\n